Sivelestat

• UNSPSC Description:

  Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19[1][2][3][4].

• Target Antigen:

  Elastase; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sivelestat.html

• Solubility:

  DMSO : ≥ 100 mg/mL|Ethanol : 3.03 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C)C(OC1=CC=C(S(=O)(NC2=CC=CC=C2C(NCC(O)=O)=O)=O)C=C1)=O

• Molecular Weight:

  434.46

• References & Citations:

  [1]Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177(2):814-20.|[2]Yuichiro Toda, et al. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Int J Mol Med. 2007 Feb;19(2):237-43.|[3]Tomoharu Kono, et al. Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia-reperfusion injury in the rat bladder. Mol Cell Biochem. 2008 Apr;311(1-2):87-92.|[4]Adeleh Sahebnasagh, et al. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther. 2020 Aug 28.Biofabrication. 2021 Feb 1.|Brain Behav Immun. 2024 Jun 12:120:403-412.|Burns Trauma. 17 September 2021.|Cancers (Basel). 2022, 14(3), 515.|Cell Biosci. 2022 Jul 22;12(1):114.|Ecotoxicol Environ Saf. 2023 Nov 18:268:115694.|Elife. 2022 Mar 23:11:e77444.|FASEB J. 2024 Dec 15;38(23):e70238.|Heliyon. 2024 Oct 5;10(19):e38895.|J Cell Mol Med. 2022 Feb 11.|J Exp Med. 2023 Sep 4;220(9):e20221751.|J Infect Dis. 2023 Nov 28:jiad526.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Res Sq. 2024 Jul 30.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2023 Dec 11.|J Hepatocell Carcinoma. 2021 May 20;8:451-465.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Oxid Med Cell Longev. 2019 Nov 23;2019:7323986.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  127373-66-4